Isomorphic Labs, the Google DeepMind spinout applying AI to drug discovery, closed a $2.1 billion Series B on May 13, 2026, led by Thrive Capital. New investors include MGX, Temasek, CapitalG, and the UK Sovereign AI Fund alongside existing backers Alphabet and GV. Proceeds fund the IsoDDE drug design engine and international expansion of the company's clinical pipeline across multiple therapeutic modalities.